Serina Therapeutics

Serina Therapeutics, founded with a mission to revolutionize drug delivery, focuses on developing polymer-based treatments for cancer, inflammation, pain, and metabolic disorders. Utilizing its proprietary POZ Platform™, the company offers programmable, targeted delivery of small molecules through customizable routes such as IV, SC, or IM. This technology allows for continuous drug delivery via once-weekly subcutaneous injections, aiming to enhance patient outcomes across various clinical indications.

Notable figures affiliated with Serina Therapeutics include experts in polymer science and pharmaceutical development. The company has secured investments from prominent venture capital firms and has achieved significant milestones, including clinical demonstrations of their POZ platform's safety and efficacy. Serina Therapeutics' innovative approach has the potential to significantly impact the treatment landscape for chronic and severe conditions, offering new hope for patients worldwide.